In the news release, "ISOThrive Awarded $800K Virginia Catalyst Grant to address major
unmet need in gastroesophageal reflux disease (GERD) treatment and
drive economic growth in Virginia," issued 26-Oct-2020 by ISOThrive Inc. over PR Newswire,
we are advised by the company that the link in the sixth paragraph,
last sentence, should be hyperlinked to
https://pharma.isothrive.com/ rather than
"http://www.isothrive.com/" as originally issued inadvertently. The
complete, corrected release follows:
ISOThrive Awarded $800K Virginia Catalyst Grant to address major
unmet need in gastroesophageal reflux disease (GERD) treatment and
drive economic growth in Virginia
HEALDSBURG, Calif.,
Oct. 26, 2020 /PRNewswire/ --
ISOThrive Inc. has been awarded $800,000 from Virginia Catalyst to advance its
microbiome therapeutic for Gastroesophageal Reflux Disease (GERD).
The funding will support a Phase 2A clinical study in collaboration
with Eastern VA Medical School,
University of VA and George Mason
University. The team is studying a proprietary microbiome
therapeutic, maltosyl-isomaltooligosaccharide (MIMO™), for the
treatment of GERD, and potential for reducing risk of Barrett's
Esophagus and esophageal adenocarcinoma.
The project was chosen by a peer reviewed panel of CEOs,
investors, scientists, and medical professionals in the life
sciences sector and is one of just three grants awarded in this
cycle totaling $2.1 million.
"Having such a strong vote of confidence by our industry peers on
the review panel and the Catalyst Board is a big endorsement of our
innovative technology to reduce microbiome-induced inflammation,"
said Jack Oswald, ISOThrive
CEO, CTO and Co-founder.
"The Catalyst Board was unanimous in selecting ISOThrive's
innovative research," said Mike
Grisham, President and CEO, Virginia
Catalyst. "ISOThrive was awarded the highest amount of
funding that can be provided because we believe this project can
propel Virginia to the forefront of microbiome research and
commercialization."
A $7.3B market opportunity of GERD
sufferers could benefit. Proton Pump Inhibitors (PPIs) such
as Omeprazole, Prilosec (P&G), Prevacid, Dexilant (Takeda),
Protonix (Pfizer), Nexium (AstraZeneca), and Aciphex (Eisai) are
the most prescribed treatment for GERD. Long-term PPI use may
be linked to serious health consequences, 40% of patients don't get
sufficient relief and 46% want to stop using them.
"Having researched and treated esophageal diseases for over 40
years, it's clear now that inflammation resulting from microbiome
dysbiosis plays a key role in GERD," said David Johnson MD MACG FASGE MACP, Professor,
Chief of Gastroenterology at Eastern VA
Medical School and a leading investigator. "ISOThrive's
unique approach to treatment by reducing inflammation is a
transformational science and a game changer."
ABOUT ISOThrive
ISOThrive Inc. is a clinical stage microbiome therapeutics
company. Initially focused on upper GI diseases such as GERD,
the company has developed two key platforms: Lightning™ for rapid
drug discovery, and Rosetta™ for precision personalized microbiome
medicine, with a pipeline of products targeted at other gut related
diseases such as IBS and colorectal cancer.
pharma.ISOThrive.com
CONTACT:Jack Oswald, info@isothrive.com, 855-552-5572
View original
content:http://www.prnewswire.com/news-releases/isothrive-awarded-800k-virginia-catalyst-grant-to-address-major-unmet-need-in-gastroesophageal-reflux-disease-gerd-treatment-and-drive-economic-growth-in-virginia-301158605.html
SOURCE ISOThrive Inc.